The role of kidney in glucose homeostasis-SGLT2 inhibitors, a new approach in diabetes treatment

被引:17
作者
Andrianesis, Vasileios [1 ]
Doupis, John [1 ,2 ]
机构
[1] Salamis Naval Hosp, Dept Internal Med & Diabet, Salamis, Greece
[2] Iatriko P Falirou Med Ctr, Div Diabet, Athens, Greece
关键词
canagliflozin; dapagliflozin; glucosuria; renal gluconeogenesis; SGLT2 Na (+)/ D-glucose co-transporters; SGLT2; inhibitors; INADEQUATE GLYCEMIC CONTROL; AFFINITY NA+/GLUCOSE COTRANSPORTER; SELECTIVE SGLT2 INHIBITOR; PROXIMAL TUBULAR CELLS; DOUBLE-BLIND; RENAL GLUCOSURIA; REMOGLIFLOZIN ETABONATE; ADD-ON; SODIUM; DAPAGLIFLOZIN;
D O I
10.1586/17512433.2013.827399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The role of the kidney in blood glucose-level regulation was until recently underestimated. Renal gluconeogenesis, renal glucose uptake and tubular glucose reabsorption are the three ways of renal involvement in glucose homeostasis. In the postabsorptive state, 20% of total glucose release is attributed to renal gluconeogenesis. Tubular glucose reabsorption is performed by the combined action of Na (+)/ D- glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and postprandial blood glucose level and slight body weight and systolic blood pressure decrease. The most common adverse events of them are genital mycotic and urinary tract infections. Dapagliflozin and canagliflozin are the first agents of this class, approved from the European Medicine Agency and FDA, respectively.
引用
收藏
页码:519 / 539
页数:21
相关论文
共 99 条
[31]   MOLECULAR PHYSIOLOGY OF SODIUM-GLUCOSE COTRANSPORTERS [J].
HEDIGER, MA ;
RHOADS, DB .
PHYSIOLOGICAL REVIEWS, 1994, 74 (04) :993-1026
[32]   Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2 [J].
Hummel, Charles S. ;
Lu, Chuan ;
Loo, Donald D. F. ;
Hirayama, Bruce A. ;
Voss, Andrew A. ;
Wright, Ernest M. .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2011, 300 (01) :C14-C21
[33]   Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus [J].
Hussey, Elizabeth K. ;
Clark, Richard V. ;
Amin, Dipti M. ;
Kipnes, Mark S. ;
O'Connor-Semmes, Robin L. ;
O'Driscoll, Eilis C. ;
Leong, Jenny ;
Murray, Sharon C. ;
Dobbins, Robert L. ;
Layko, Debbi ;
Nunez, Derek J. R. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (06) :623-635
[34]  
Irony I, 2011, FDA ADV COMM M
[35]   Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes [J].
Jabbour, S. A. ;
Goldstein, B. J. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (08) :1279-1284
[36]  
Janssen Research & Development LLC, 2012, 1 RES CANVAS TRIAL S
[37]  
Johnson & Johnson, 2013, JANSS SUBM EUR MARK
[38]   THE HUMAN KIDNEY LOW-AFFINITY NA+/GLUCOSE COTRANSPORTER SGLT2 - DELINEATION OF THE MAJOR RENAL REABSORPTIVE MECHANISM FOR D-GLUCOSE [J].
KANAI, Y ;
LEE, WS ;
YOU, GF ;
BROWN, D ;
HEDIGER, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :397-404
[39]  
Kapur A, 2009, DIABETES S1A, V58, p509P
[40]   Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus [J].
Komoroski, B. ;
Vachharajani, N. ;
Feng, Y. ;
Li, L. ;
Kornhauser, D. ;
Pfister, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) :513-519